Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Marizyme, Inc., Appoints New Members to its Board of Directors | ||
By: PR Newswire Association LLC. - 14 Dec 2018 | Back to overview list |
|
FORT COLLINS, Colo., Dec. 14, 2018 /PRNewswire/ -- Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC:MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that it is appointing Mr. James Sapirstein and Mr. Terry Brostowin to the Board of Directors. In addition, the Company has accepted the resignation of Mr. Juan Francisco Gutierrez from the Board of Directors, for health reasons, and the resignation of Mr. Marco Nicolaides as the Company's Treasurer. The Company is very grateful to Mr. Gutierrez and Mr. Nicolaides for their service to the Company and their leadership during his term. Mr. Sapirstein, who has been appointed Executive Chairman, is a highly-regarded pharmaceutical industry executive with more than 35 years of success in building companies and leading the commercial launch of nearly two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. He has worked at major pharmaceutical companies including Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly, and has led commercial teams for successful biotech companies such as Gilead Sciences and Serono Laboratories. In recent years, Mr. Sapirstein has been the founding CEO of the following early-stage biotech companies - Tobira Therapeutics, Alliqua Therapeutics and most recently, Contravir Pharmaceuticals, where he defined and executed corporate strategy, raised significant capital, advanced drug development programs, and built shareholder value. Mr. Brostowin, who has been appointed as a Director, is an accomplished attorney admitted to the Federal Court in both the Eastern and Southern districts of New York. He has extensive expertise in contracts, and commercial litigation. Mr. Brostowin has advised the New York City Mayor's office on judicial appointments and was a compliance specialist ensuring agencies followed court ordered activities and ensured the financial integrity of the Financial Systems Division accounting and budgetary systems. Mr. Brostowin has been affiliated with the law firm Brostowin & Associates, PC , since 2009. From 2002 to 2009, Mr. Brostowin was affiliated with the law firm Conway & Brostowin, LLC. Mr. Handley commented, "We are excited to have James's leadership and deep biotechnology and public company experience on our Board. Terry's legal and compliance background is an excellent fit for us as well and we look forward to utilizing his capabilities. Together, these appointments bring the Company closer to its goal of becoming a leader in the field of acute care therapeutics." About Marizyme, Inc. Forward-Looking Statements
View original content:http://www.prnewswire.com/news-releases/marizyme-inc-appoints-new-members-to-its-board-of-directors-300765940.html SOURCE Marizyme, Inc. |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |